RO118175B1 - Tableta acoperita cu un film pentru utilizare terapeutica si procedeu de preparare al acesteia - Google Patents
Tableta acoperita cu un film pentru utilizare terapeutica si procedeu de preparare al acesteia Download PDFInfo
- Publication number
- RO118175B1 RO118175B1 RO97-01333A RO9701333A RO118175B1 RO 118175 B1 RO118175 B1 RO 118175B1 RO 9701333 A RO9701333 A RO 9701333A RO 118175 B1 RO118175 B1 RO 118175B1
- Authority
- RO
- Romania
- Prior art keywords
- tablet
- weight
- tablet according
- silicon dioxide
- lubricant
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- 239000007941 film coated tablet Substances 0.000 title claims abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 75
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 46
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract description 39
- 239000000314 lubricant Substances 0.000 claims abstract description 35
- 239000008187 granular material Substances 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 239000011230 binding agent Substances 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 238000005469 granulation Methods 0.000 claims abstract description 18
- 230000003179 granulation Effects 0.000 claims abstract description 18
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 13
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims abstract 33
- 235000010980 cellulose Nutrition 0.000 claims description 38
- 229920002678 cellulose Polymers 0.000 claims description 38
- 239000001913 cellulose Substances 0.000 claims description 37
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 10
- 229960000913 crospovidone Drugs 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 10
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- -1 2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl Chemical group 0.000 claims description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 9
- 229940069328 povidone Drugs 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 230000008030 elimination Effects 0.000 claims description 5
- 238000003379 elimination reaction Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 229920003082 Povidone K 90 Polymers 0.000 claims description 4
- 238000013160 medical therapy Methods 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-M valinate Chemical compound CC(C)C(N)C([O-])=O KZSNJWFQEVHDMF-UHFFFAOYSA-M 0.000 claims 1
- 238000002156 mixing Methods 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 10
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 30
- 229940093257 valacyclovir Drugs 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000005336 cracking Methods 0.000 description 7
- 239000011928 denatured alcohol Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 229920003081 Povidone K 30 Polymers 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 229960004150 aciclovir Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000007916 tablet composition Substances 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005292 vacuum distillation Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- CANZBRDGRHNSGZ-NSHDSACASA-N (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-NSHDSACASA-N 0.000 description 2
- JILCEWWZTBBOFS-UHFFFAOYSA-N 4-(methylamino)antipyrine Chemical compound O=C1C(NC)=C(C)N(C)N1C1=CC=CC=C1 JILCEWWZTBBOFS-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- CGTZMJIMMUNLQD-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCOC1=CC=CC=C1OC(C=1C=CC=CC=1)C1OCCNC1 CGTZMJIMMUNLQD-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-Valine Natural products CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-M L-valinate Chemical compound CC(C)[C@H](N)C([O-])=O KZSNJWFQEVHDMF-BYPYZUCNSA-M 0.000 description 1
- JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000870363 Oryctolagus cuniculus Glutathione S-transferase Yc Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- BQIVJVAZDJHDJF-LURJTMIESA-N ethyl (2s)-2-amino-3-methylbutanoate Chemical compound CCOC(=O)[C@@H](N)C(C)C BQIVJVAZDJHDJF-LURJTMIESA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960002614 lanatoside c Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000011163 secondary particle Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9501127.6A GB9501127D0 (en) | 1995-01-20 | 1995-01-20 | Tablet |
| PCT/GB1996/000111 WO1996022082A1 (en) | 1995-01-20 | 1996-01-19 | Valaciclovir tablets containing colloidal silicon dioxide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RO118175B1 true RO118175B1 (ro) | 2003-03-28 |
Family
ID=10768317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RO97-01333A RO118175B1 (ro) | 1995-01-20 | 1996-01-19 | Tableta acoperita cu un film pentru utilizare terapeutica si procedeu de preparare al acesteia |
Country Status (38)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| CA2243237C (en) * | 1996-01-19 | 2008-09-02 | Glaxo Group Limited | Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application |
| AR017512A1 (es) * | 1997-08-22 | 2001-09-12 | Smithkline Beecham Corp | Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas |
| AR016827A1 (es) | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| BR9916361A (pt) * | 1998-12-18 | 2002-11-05 | Abbott Lab | Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia |
| GB0010446D0 (en) * | 2000-04-28 | 2000-06-14 | Glaxo Wellcome Kk | Pharmaceutical formulation |
| UA75135C2 (en) * | 2001-05-01 | 2006-03-15 | Pfizer Prod Inc | Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions |
| US7815936B2 (en) * | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| AU2002348022B2 (en) * | 2001-11-05 | 2006-06-15 | Glaxo Group Limited | Anhydrous crystal form of valaciclovir hydrochloride |
| CA2465928C (en) * | 2001-11-14 | 2010-01-19 | Teva Pharmaceutical Industries Ltd. | Synthesis and purification of valacyclovir |
| GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| EP1517678A2 (en) * | 2002-06-24 | 2005-03-30 | Ranbaxy Laboratories Limited | Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| US20050051922A1 (en) * | 2002-09-20 | 2005-03-10 | Avinash Nangia | Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same |
| WO2004035583A1 (en) * | 2002-10-16 | 2004-04-29 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20050059684A1 (en) * | 2002-10-16 | 2005-03-17 | Ben-Zion Dolitzky | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20040109889A1 (en) * | 2002-12-04 | 2004-06-10 | Bunick Frank J. | Surface treatment composition for soft substrates |
| WO2004106338A1 (en) * | 2003-05-30 | 2004-12-09 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. | Novel crystalline forms of valacyclovir hydrochloride |
| EP2014660A3 (en) * | 2003-06-02 | 2009-07-15 | Teva Pharmaceutical Industries Ltd | Novel crystalline forms of valacyclovir hydrochloride |
| US7632521B2 (en) * | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
| HUE044822T2 (hu) | 2003-09-12 | 2019-11-28 | Amgen Inc | Cinakalcet HCl gyors feloldódású készítménye |
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| EP1541133B1 (en) * | 2003-12-09 | 2005-08-10 | Helm AG | Pharmaceutical formulation of valaciclovir |
| US7344907B2 (en) * | 2004-11-19 | 2008-03-18 | International Business Machines Corporation | Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale |
| KR101116747B1 (ko) | 2004-12-06 | 2012-02-22 | 에스케이케미칼주식회사 | 안정성이 개선된 말레인산 암로디핀 약제 조성물 |
| DK1868579T3 (da) | 2005-03-07 | 2011-01-10 | Bayer Schering Pharma Ag | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer |
| ATE546451T1 (de) * | 2005-05-25 | 2012-03-15 | Lilly Co Eli | Cyclopropancarbonsäureester von acyclovir |
| EP1746098A1 (en) * | 2005-07-21 | 2007-01-24 | SOLMAG S.p.A. | Valacyclovir polymorphs and a process for the preparation thereof |
| WO2007090595A1 (en) * | 2006-02-06 | 2007-08-16 | Fidia Pharmaceutici S.P.A. | Solid formulations of valacyclovir hydrochloride |
| JP2009536165A (ja) * | 2006-05-10 | 2009-10-08 | エボニック デグサ ゲーエムベーハー | 医薬組成物におけるロール圧縮された熱分解的に製造された二酸化ケイ素の使用 |
| EP2037887B1 (en) * | 2006-05-31 | 2010-09-15 | Vertex Pharmaceuticals Incorporated | Oral controlled release formulations of an interleukin-1 beta converting enzyme inhibitor |
| US20090291136A1 (en) * | 2006-07-11 | 2009-11-26 | Lek Pharmaceuticals D.D. | Multiple Unit Tablets |
| US20080167325A1 (en) * | 2006-12-27 | 2008-07-10 | Bs Praveen Kumar | Valacyclovir compositions |
| US20090076039A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched valacyclovir |
| ITRM20080027A1 (it) * | 2008-01-18 | 2009-07-19 | Maria Balestrieri | Uso di aciclovir per il trattamento delle condilomatosi. |
| US20100124560A1 (en) * | 2008-11-14 | 2010-05-20 | Mcneil Ab | Multi portion intra-oral dosage form and use thereof |
| DK2407166T3 (da) * | 2009-03-13 | 2013-10-07 | Toyama Chemical Co Ltd | Tablet og granuleret pulver indeholdende 6-fluor-3-hydroxy-2-pyrazin-carboxamid |
| CH703348A1 (de) * | 2010-06-29 | 2011-12-30 | Mepha Gmbh | Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen. |
| GB2515486A (en) * | 2013-06-24 | 2014-12-31 | Kraft Foods R & D Inc | Soluble Beverage Ingredients |
| KR101497508B1 (ko) * | 2013-12-20 | 2015-03-03 | 한국유나이티드제약 주식회사 | 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법 |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| WO2020049536A1 (en) * | 2018-09-07 | 2020-03-12 | Jubilant Generics Limited | Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof |
| CN110279667B (zh) * | 2019-07-30 | 2023-02-10 | 珠海润都制药股份有限公司 | 一种盐酸伐昔洛韦片及其制备方法 |
| EP4157221A4 (en) * | 2020-06-01 | 2024-07-24 | Shilpa Medicare Limited | RAPIDLY DISPERSABLE PHARMACEUTICAL COMPOSITION CONTAINING CAPECITABINE |
| TWI884340B (zh) * | 2020-12-01 | 2025-05-21 | 南韓商Ｌｇ化學股份有限公司 | 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法 |
| CA3266275A1 (en) * | 2022-08-31 | 2024-03-07 | Astrazeneca Ab | PHARMACEUTICAL FORMULATION |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1259924A (en) * | 1985-03-25 | 1989-09-26 | Wallace E. Becker | Pharmaceutical tableting method |
| AP55A (en) * | 1987-08-15 | 1989-09-26 | The Wellcome Foundation Ltd | Therapeutic Acyclic Nucleosides |
| EP0349103B1 (en) * | 1988-05-04 | 1992-11-25 | Smith Kline & French Laboratories Limited | Chewable tablet |
| ATE133068T1 (de) * | 1991-01-30 | 1996-02-15 | Wellcome Found | Wasserlösliche tabletten |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| GB9317146D0 (en) * | 1993-08-18 | 1993-10-06 | Wellcome Found | Therapeutic combinations |
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
-
1995
- 1995-01-20 GB GBGB9501127.6A patent/GB9501127D0/en active Pending
-
1996
- 1996-01-19 JP JP52212696A patent/JP3350055B2/ja not_active Expired - Fee Related
- 1996-01-19 ZA ZA96448A patent/ZA96448B/xx unknown
- 1996-01-19 DK DK96900626T patent/DK0806943T3/da active
- 1996-01-19 CN CNB2003101029136A patent/CN1313081C/zh not_active Expired - Fee Related
- 1996-01-19 AP APAP/P/1997/001057A patent/AP666A/en active
- 1996-01-19 TR TR97/00657T patent/TR199700657T1/xx unknown
- 1996-01-19 DE DE69607146T patent/DE69607146T2/de not_active Expired - Lifetime
- 1996-01-19 MY MYPI96000222A patent/MY126346A/en unknown
- 1996-01-19 GE GEAP19963844A patent/GEP20022752B/en unknown
- 1996-01-19 EE EE9700352A patent/EE03336B1/xx not_active IP Right Cessation
- 1996-01-19 CZ CZ0229297A patent/CZ296514B6/cs not_active IP Right Cessation
- 1996-01-19 CA CA002210891A patent/CA2210891C/en not_active Expired - Fee Related
- 1996-01-19 EA EA199700123A patent/EA000276B1/ru not_active IP Right Cessation
- 1996-01-19 WO PCT/GB1996/000111 patent/WO1996022082A1/en not_active Ceased
- 1996-01-19 PT PT96900626T patent/PT806943E/pt unknown
- 1996-01-19 EP EP96900626A patent/EP0806943B1/en not_active Expired - Lifetime
- 1996-01-19 SK SK964-97A patent/SK282030B6/sk not_active IP Right Cessation
- 1996-01-19 US US08/875,172 patent/US5879706A/en not_active Expired - Lifetime
- 1996-01-19 BR BR9606769A patent/BR9606769A/pt not_active IP Right Cessation
- 1996-01-19 IL IL11683096A patent/IL116830A/xx not_active IP Right Cessation
- 1996-01-19 NZ NZ298846A patent/NZ298846A/en not_active IP Right Cessation
- 1996-01-19 AU AU44534/96A patent/AU710823B2/en not_active Ceased
- 1996-01-19 CN CN96192661A patent/CN1131026C/zh not_active Expired - Fee Related
- 1996-01-19 AT AT96900626T patent/ATE190483T1/de not_active IP Right Cessation
- 1996-01-19 KR KR1019970704915A patent/KR100412298B1/ko not_active Expired - Lifetime
- 1996-01-19 HU HU9801872A patent/HU226131B1/hu not_active IP Right Cessation
- 1996-01-19 RO RO97-01333A patent/RO118175B1/ro unknown
- 1996-01-19 ES ES96900626T patent/ES2145425T3/es not_active Expired - Lifetime
- 1996-01-19 UA UA97084269A patent/UA68325C2/uk unknown
- 1996-01-19 IN IN100MA1996 patent/IN181318B/en unknown
-
1997
- 1997-07-16 OA OA70052A patent/OA10500A/en unknown
- 1997-07-18 PL PL96321361A patent/PL185307B1/pl not_active IP Right Cessation
- 1997-07-18 FI FI973062A patent/FI119722B/fi not_active IP Right Cessation
- 1997-07-18 NO NO19973327A patent/NO311488B1/no not_active IP Right Cessation
- 1997-08-14 BG BG101831A patent/BG63187B1/bg unknown
-
1999
- 1999-10-28 UY UY25774A patent/UY25774A1/es unknown
- 1999-10-29 UY UY25778A patent/UY25778A1/es not_active IP Right Cessation
-
2000
- 2000-06-14 GR GR20000401364T patent/GR3033677T3/el not_active IP Right Cessation
- 2000-08-23 CY CY0000042A patent/CY2182B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RO118175B1 (ro) | Tableta acoperita cu un film pentru utilizare terapeutica si procedeu de preparare al acesteia | |
| US8435564B2 (en) | Pharmaceutical compositions comprising brivaracetam | |
| NO315558B1 (no) | Vannfri krystallinsk form av valaciclovir-hydroklorid | |
| JP2009500318A (ja) | 新規な徐放性医薬組成物とその製法 | |
| JP4097698B2 (ja) | 一日一回の投与による陰部ヘルペス治療用医薬の製造のためのバラシクロビールの使用 | |
| RU2329789C2 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ N-[(1-nБУТИЛ-4-ПИПЕРИДИНИЛ)МЕТИЛ]-3,4-ДИГИДРО-2Н-[1,3]ОКСАЗИНО [3,2-a]ИНДОЛ-10-КАРБОКСАМИД ИЛИ ЕГО СОЛЬ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ, ВКЛЮЧАЮЩИЙ СУХУЮ ГРАНУЛЯЦИЮ | |
| MXPA97005459A (en) | Valaciclovir tablets containing silicon dioxide color | |
| HK1002851B (en) | Valaciclovir tablets containing colloidal silicon dioxide | |
| JPH1160483A (ja) | Ｔｎｆ産生阻害剤 |